ABL Texcell Diagnostics buys IntegraGen assets for EUR 100,000 in Evry court deal

• ABL Diagnostics agreed to acquire IntegraGen’s assets and business operations under an Evry Commercial Court ruling dated Oct. 9, 2026.
• Purchase price totals EUR 100,000, including EUR 95,000 for assets and EUR 5,000 for inventories.
• Deal adds clinical genomics and precision-oncology capabilities, including NGS services, bioinformatics software, and minimal residual disease technologies.
• Integration plan includes EUR 150,000 of initial investment, with restart and integration funding needs estimated at about EUR 900,000.
• Operations will continue at IntegraGen’s Evry site at Genopole, with 16 employees transferring as part of the transaction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ABL Diagnostics SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20261011071324) on October 12, 2026, and is solely responsible for the information contained therein.